OncoMatch/Leukemia — Chronic Lymphocytic (CLL)/BTK (ibrutinib resistance)
Leukemia — Chronic Lymphocytic (CLL)BTK (ibrutinib resistance) Clinical Trials
1 recruiting trials·Updated daily from ClinicalTrials.gov
BTK C481S and other kinase domain mutations are the primary mechanism of acquired ibrutinib resistance in CLL, occurring in approximately 50–80% of ibrutinib-resistant cases. Non-covalent BTK inhibitors (pirtobrutinib) are FDA-approved for BTK-inhibitor-pretreated CLL, maintaining activity against C481 mutations. Trials investigate pirtobrutinib combinations, BTK PROTAC degraders, and venetoclax-based salvage after BTK inhibitor failure.
Top recruiting
Top recruiting BTK (ibrutinib resistance) Leukemia — Chronic Lymphocytic (CLL) trials
Ranked by phase and US site count. See all 1 trials matched to your profile →
Other Leukemia — Chronic Lymphocytic (CLL) biomarkers
Browse other molecular targets with active Leukemia — Chronic Lymphocytic (CLL) trials.